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The Mads/Mef2 (Mef2a/b/c/d) family of transcription factors (TFs) regulates differentiation
of muscle cells, neurons and hematopoietic cells. By functioning in physiological feedback
loops, Mef2 TFs promote the transcription of their repressor, Hdac9, thereby providing
temporal control of Mef2-driven differentiation. Disruption of this feedback is associated
with the development of various pathologic states, including cancer. Beside their direct
involvement in oncogenesis, Mef2 TFs indirectly control tumor progression by regulating
antitumor immunity. We recently reported that in CD4+CD25+Foxp3+ T-regulatory (Treg)
cells, Mef2d is required for the acquisition of an effector Treg (eTreg) phenotype and for the
activation of an epigenetic program that suppresses the anti-tumor immune responses of
conventional T and B cells. We now report that as with Mef2d, the deletion of Mef2c in
Tregs switches off the expression of Il10 and Icos and leads to enhanced antitumor
immunity in syngeneic models of lung cancer. Mechanistically, Mef2c does not directly
bind the regulatory elements of Icos and Il10, but its loss-of-function in Tregs induces the
expression of the transcriptional repressor, Hdac9. As a consequence, Mef2d, the more
abundant member of the Mef2 family, is converted by Hdac9 into a transcriptional
repressor on these loci. This leads to the impairment of Treg suppressive properties in
vivo and to enhanced anti-cancer immunity. These data further highlight the central role
played by the Mef2/Hdac9 axis in the regulation of CD4+Foxp3+ Treg function and adds a
new level of complexity to the analysis and study of Treg biology.
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The role played by Treg cells in restraining anti-tumor immunity (1)
and in limiting transplant rejection (2) is well established and has
made the study of Treg differentiation, stability, subpopulations and
homeostasis a major focus of immunology (3). Foxp3 is the master
transcription factor (TF) involved in sustaining Treg suppressive
identity and mutations leading to Foxp3 loss-of-function are
associated clinically with the severe autoimmunity that presents as
IPEX syndrome (Immune dysregulation, Polyendocrinopathy,
Enteropathy, X-linked) (4–6). However, Foxp3 has been
demonstrated to be necessary, but not sufficient, for triggering
and maintaining the Treg phenotype (7). The exceptional interest
in Treg biology has made Foxp3 one of the most studied TFs so far
(8). Foxp3 transcriptional activities are finely modulated through
four main mechanisms: i) the transcriptional and post-translational
regulation of its expression (9); ii) the heterogeneity of Foxp3
partners involved in sustaining (9), but also positively or
negatively modulating its transcriptional functions (10); iii) the
large number of epigenetic regulators that act as pioneering
factors (11, 12) or plastically modulate Foxp3 activities (13, 14);
and iv) the protein-protein complexes and transcription factors that
antagonistically or agonistically integrate Foxp3 responses (15–17).
We recently identified Mef2d as a TF that supports and
integrates the transcriptional responses of Foxp3, allowing Tregs
to acquire the phenotype of effector Tregs (eTregs) (18). Similarly to
Foxp3, the four Mef2 paralogues (Mef2a, b, c, d) assemble into
multi-protein complexes which modulate the resulting
transcriptional responses to control various and complex
differentiative and adaptive programs (19, 20). The dynamic
nature of Mef2 protein complexes has been little investigated in T
effector cells and is completely unexplored in Treg cell. Here, by
exploring the roles of Mef2c in CD4+ Foxp3+ Treg cells, we
discovered the existence of a feed-back circuit involving Mef2c,
Mef2d and Hdac9. Interference in this circuit decreases the
immunosuppressive properties of Foxp3+ Tregs in vivo. Our
results stress the need to deepen the study of this signaling
pathway so as to more fully understand the transcriptional
dynamics of Treg cells.MATERIALS AND METHODS
Mice
BALB/c and C57BL/6 mice were purchased from The Jackson
Laboratory. Foxp3YFP-cremice (21) andMef2cflox/floxmice (22) were
previously described and backcrossed on the C57BL/6 background
at least 8 times.Micewith conditional deletionofMef2cwithin their
Foxp3+ Treg cells (Foxp3YFP-creMef2cflox/flox) are hereafter listed as
Mef2c-/- mice. Foxp3YFP-cre mice were used as wild-type controls.
Co-Immunoprecipitation
and Western Blotting
Teff and Treg cells were lysed with hypotonic buffer (20 mM
Tris-HCl, pH 7.5; 2 mM EDTA; 10 mM KCl; 1% Triton X-100),
supplemented with protease and phosphatase inhibitors; 1 mg of
antibody (Ab) was used for immunoprecipitation, and Protein-GFrontiers in Immunology | www.frontiersin.org 2agarose (Invitrogen, #15920-010) was used to collect Ab-antigen
complexes. Cell lysates were separated by SDS-PAGE, transferred to
nitrocellulose membranes and immunoblotted with the following
Abs: Mef2d (Becton-Dickinson, #610774), Foxp3 (Invitrogen,
#700914), b-actin (Cell Signaling Technology, #3700), and Hdac9
(23). Secondary HRP-conjugated Abs to mouse (#7076), rat (#7077)
and rabbit (#7074) IgG were purchased from Cell Signaling
Technology. Unconjugated CD3 (clone 145-2C11, #553057) and
CD28 (clone 37.51, #553294) mAbs used for cell activation were
purchased from Becton-Dickinson.
Flow Cytometry
Single-cell suspensions from secondary lymphoid tissues or
tumors were prepared as previously described (15) and stained
with fluorochrome-conjugated mAbs directed against CD4
(Pacific blue, Invitrogen, #MHCD0428), CD8 (Super Bright
645, eBioscience, clone 53-6.7, #64-0081-82), Foxp3 (eFluor
450, eBioscience, clone FJK-16s, #48-5773-82 and PE-Cy5 #15-
5773-82), CD62L (PE-Cy7, clone MEL-14, #25-0621-82), IFN-g
(APC, clone XMG1.2, #554413; PE # 554412), CD44 (PE-Cy5,
eBioscience, clone IM7, #15-0441-83), Ctla4 (APC, #17-1522-
82), Icos (PE, # 12-9949-81), CD25 (APC, eBioscience, clone
PC61.5, #17-0251-82), and CD8a (FITC, #53-6.7), and acquired
on a Cytoflex (Beckman Coulter) flow cytometer.
Treg Suppression Assays
5×104 CD4+CD25- conventional T cells and CD4+CD25+Tregs
from Foxp3YFP-Cre and Mef2c-/-mice were isolated using
CD4+CD25+Treg isolation kits (Miltenyi Biotec, #130-091-
041) and seeded into 96-well plates. Equal numbers of CFSE-
labeled CD4+CD25- T cells and g-irradiated antigen-presenting
cells (CD90.2–, Miltenyi Biotec, #130-049-101), plus CD3 mAb
(1 mg/ml), were cultured for 72 h with different concentrations of
Tregs. After 72 h, proliferation of conventional T cells was
determined by flow cytometry and analysis of CFSE dilution.
Cardiac Transplantation
We undertook heterotopic cardiac allografting using BALB/c
mice as donors and WT or Mef2c-/- C57BL/6 mice as recipients.
On the day of engraftment, recipients were treated i.v. with
CD154 mAb (Bio X Cell, clone MR-1, #BE0017-1, 200 µg) plus
5×106 donor splenocytes (DST) (24). Allograft survival was
monitored by palpation of ventricular contractions and
subsequently confirmed by histological evaluation.
ChIP Assays
Each ChIP was performed using 3×106 Tregs. After 15’ of
fixation with 1% formaldehyde and 30 cycles of sonication (30
sec ON and 30 sec OFF, Bioruptor, Diagenode), the resulting
chromatin was immunoprecipitated using Abs against H3K27ac
(2µg, Abcam #ab4729), Mef2d (5 µg, BD, # 610774), Mef2c (5 µg)
(25), and Hdac9 (5 µg) (23). The immunoprecipitated DNA was
purified and analyzed by qPCR (SYBR green, KAPA).
RNA-Seq and Real-Time qPCR
RNeasy kits (QIAGEN) were used to isolate mRNA. mRNA with
a RIN>7 were used to prepare libraries and performJuly 2021 | Volume 12 | Article 703632
Di Giorgio et al. Mef2c and Foxp3+ Treg CellsRNA-sequencing by Novogene (Sacramento, CA) on the
Illumina Platform PE150. The edgeR package was used to
identify the differentially expressed genes (p-value <0.05 and
fold change >1.3). GSEA (26) was performed to interrogate
datasets with defined genesets, as described (27). The
expression levels of individual genes were verified by qPCR.
For this purpose, RNA was reverse transcribed to cDNA
(Applied Biosystems) and Taqman primers and probe sets
were used to perform RT-qPCR. Data were normalized to
endogenous 18s and relative expression was determined by the
formula 2–DCT.
Cell Lines and Tumor Models
The murine lung adenocarcinoma cell line, TC1 (28), was
provided by Dr. Yvonne Patterson (UPenn, Philadelphia, PA).
Lung cancer cells were grown in RPMI supplemented with 10%
fetal bovine serum (FBS), 2 mM glutamine, and 5 mg/ml
penicillin & streptomycin. For lung tumor cells, each mouse
was injected s.c. with 1.2×106 TC1 tumor cells. Tumor volume
was determined by the formula: ((short diameter)2 × long
diameter)/2.
Statistical analysis
Data were analyzed using GraphPad Prism 8.0 and Excel. Data
are presented as mean ± standard error. Statistical comparisons
between two groups were done with a 2-tailed Student’s t test.
Comparisons between multiple samples were performed by
using a 1-way ANOVA test with corresponding Tukey’s
multiple comparison test. Graft survival was evaluated with
Kaplan-Meier followed by log-rank test. We marked with
*p<0.05, **p<0.01, ***p<0.005.
Study Approval
Animal studies were approved by the Institutional Animal Care
and Use Committee of the Children’s Hospital of Philadelphia
(protocols 17-001047 and 19-000561).
Primers
The following primers were used for ChIP-qPCR analysis: Itk
FW: GTGCGACTGAAGGAGAGGAG, Itk RV: CATCAGAG
GAGGGAGCTCAG , Hda c9 FW: CTCCAGAGGG
TGTCCTCCTA, Hdac9 RV: GGCTTTGGTGGGGTATTTTT,
Icos 1 FW: CCTCAGTCAGAAGGGTCGTC, Icos 1 RV: CAGA
AATTCCTGGTCATGTTTT, Icos 2 FW: AGTCTGCCATAG
GGTTGGTG, Icos 2 RV: TCAGTCATTTTCTCCCCCTTT, Il10
FW: TCTTTAGCGCTTACAATGCAAA , I l 10 RV :
CTGTTCTTGGTCCCCCTTTT.RESULTS
Mef2c Deletion in Tregs Only Partially
Represses Their Suppressive Properties
In Vitro
As noted in the literature, the various paralogues of MEF2
can play redundant (29, 30) or differentiative and adaptiveFrontiers in Immunology | www.frontiersin.org 3roles (31, 32). Despite its low expression in murine Tregs
(Figure 1A), we deleted Mef2c expression in Foxp3+ Treg cells
by crossing Mef2cfl/fl mice and Foxp3YFP/Cre mice so as to
investigate the existence of alternative, supplementary or
redundant transcriptional programs with respect to those
controlled by Mef2d, its more abundant paralogue. Mef2cfl/fl
Foxp3YFP/Cre (hereafter Mef2c-/-) mice were born at expected
Mendelian ratios and were characterized by normal numbers of
Tregs in secondary lymphoid tissues, though CD4+Foxp3+
Tregs were increased in the thymus of Mef2c-/- mice
(Figures 1B, C). Whether this was due to increased
generation, stability or re-circulation to the thymus is presently
unknown, but was previously also observed in Mef2dfl/
flFoxp3YFP/Cre mice (18). The in vitro suppressive functions of
Mef2c-/- Tregs were increased, as shown by cell-sorting
(Figure 1D) and testing of the ability of purified Tregs to
inhibit the proliferation of conventional T cells. Area-under-
curve data are shown in Figure 1E and a triplicate assay,
representative of 2 such assays, is shown in Figure 1F.
Assessment of suppressive activity again CD4 and CD8 T cell
subsets is shown in Supplementary Figure 1. Hence, while
Mef2d deletion in Tregs led to decreased suppressive function
in vitro (18), Mef2c deletion had an opposite effect.
General Mef2 Signatures but Also
Treg-Specific Signatures Are Altered
in Mef2c-/- Tregs
Despite the low expression levels of Mef2c in murine Tregs,
the impact of Mef2c deletion on the Treg transcriptome was
very similar to what we observed upon Mef2d deletion (18).
That is, Mef2d deletion caused the up-regulation of 795
transcripts and the repression of 700 genes (18), while Mef2c
deletion caused the up-regulation of 801 genes and the
repression of 729 genes (>1.3-fold, p<0.05) (Figure 2A). Gene
set enrichment analysis (GSEA) showed that in Tregs, Mef2c
controls general transcriptional responses previously associated
with Mef2 TFs in different cell types, like E2F and peroxisome
proliferator-activated receptor-g agonists/retinoic acid signaling
(Figure 2B). Alongside the perturbation of these signaling
pathways, we found that Mef2c controls the expression of
more specific signatures related to the activation of Tregs and
the execution of their immunosuppressive properties
(Figure 2B). This analysis suggests that Mef2c is required to
sustain the activation of Tregs and the transcriptional program
activated by Blimp1 (Figure 2B). We validated the RNA-seq data
by means of qRT-PCR on a selected pool of transcripts found to
be dysregulated after Mef2c depletion; in each case there was
agreement with the high-throughput data (Figure 2C).
Mef2c Depletion Switches on Hdac9
Transcription and Triggers a Feedback
Response That Limits the Transcriptional
Activity of Mef2d
GSEA analysis showed that many aspects of the transcriptional
perturbation obtained after the depletion of Mef2c in Tregs are
superimposable to that obtained by depleting Mef2dJuly 2021 | Volume 12 | Article 703632
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organization of Mef2d transcriptional complexes achieved as a
consequence of Mef2c KO. Though suggested many times in the
literature (23, 27, 31, 34–37), the stoichiometry as well as the
dynamic composition of MEF2 heterodimeric complexes inFrontiers in Immunology | www.frontiersin.org 4living cells have never been investigated in detail. We
approached this issue by looking at the perturbations of
mRNA abundance of the privileged partners of MEF2 TFs
observed after Mef2c or Mef2d depletion (Figure 3B). Among




FIGURE 1 | Mef2c deletion in Tregs increases their suppressive properties in vitro. (A) mRNA absolute levels of the indicated Mef2 paralogues in Tregs, expressed
as RPKM levels relative to Mef2d levels. (B, C) Analysis of CD4+Foxp3+ in lymph nodes (LN), spleens (SP) and thymii (TH) tissues from Mef2c-/- or WT mice (n = 4,
*p < 0.05, t-test). (D) Purity of CD4+CD25+Foxp3+ Tregs used for Treg assays (representative of 3 mice/group) and performed twice (Trial 1 and Trial 2). (E) AUC
data from Treg suppression assays performed twice and in triplicate (**p < 0.01, ***p < 0.005, ***p < 0.001). (F) Examples of Treg suppression assays performed in
triplicate and using all T cells as proliferating cells (separate CD4 and CD8 T cells responses are shown in Supplementary Figure 1); the proportion of proliferating T
cells within each panel is shown in blue.July 2021 | Volume 12 | Article 703632
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We confirmed this upregulation in Mef2c-/- Tregs both at the
RNA (Figure 3C) and protein (Figure 3D) levels, and that
upregulation was likely to be due to increased transcription as
a consequence of the establishment of a proficient chromatin
environment at the promoter level (Figure 3E).
Increased levels of Hdac9 can flip the balance of protein
complexes assembled on Mef2d, thus altering its transcriptional
effects (23, 38, 39). Indeed, most of the transcripts repressed in
Mef2c-/- Tregs (Figure 3F) were upregulated in Hdac9-/- Tregs
(33, 40). Levels of Mef2d engaged in protein complexes with
Hdac9 in Mef2c-/- Tregs were almost double that of WT Tregs
(Figure 3G). In Mef2c-/- Tregs, this resulted in the establishment
of a repressive chromatin at the level of the Mef2d-bound (18)
regulative elements of Icos and IL-10 (Figure 3H). The co-
occurrence of Hdac9 binding suggests, but does not directly
prove, its involvement in decreasing the acetylation of H3K27 on
these loci (Figure 3H). These data suggest that the release of
Hdac9 transcription achieved after Mef2c KO could be involved
in the establishment of repressive complexes on Mef2d, thus
leading to the perturbation of eTreg properties, similarly to what
we reported for Mef2d-/- Tregs (18).
Mef2c Deletion Dampens Treg
Function In Vivo
We used two animal models to assess the effects of Mef2c
deletion on Treg suppressive functions in vivo.Frontiers in Immunology | www.frontiersin.org 5First, we performed cardiac allografting using BALB/c donors
and WT or Mef2c-/- C57BL/6 recipients in the presence of co-
stimulation blockade with CD154 mAb/DST (Figure 4A) (24).
While co-stimulation blockade induced long-term allograft
survival (>100 d) in WT recipients, acute rejection was
observed in Mef2c-/- recipients (p<0.01) (Figure 4B). This was
unexpected, given that Mef2c deletion had led to increased Treg
suppressive function in vitro (Figure 1). Nevertheless, histologic
comparison of grafts harvested from the 2 groups at 21 days
post-transplant showed only focal interstitial infiltrates in WT
recipients but dense mononuclear infiltrates with multifocal
myocyte necrosis and vascular injury in conditionally deleted
Mef2c-/- recipients (Figure 4C); such Mef2c-associated
pathology is very similar to that seen previously following
Mef2d deletion in Foxp3+ Treg cells (18). Using real-time
qPCR, we compared intragraft gene expression at the 21 days
post-transplant time-point in WT vs. Mef2c-/- recipients. The
levels of CD4, CD8, CD19 and Foxp3 were comparable between
groups, as was IL-2 expression, but Mef2c-/- recipients had
increased intragraft expression of IFN-g, granzyme-B and Ctla4
(Figure 4D). Hence our in vivo allograft studies are consistent
with conditional deletion of Mef2c leading to impaired
Treg function.
Second, we studied the effects of Mef2c deletion on anti-
tumor immunity, by using syngeneic models of lung cancer (TC1
tumor cells injected subcutaneously). After the successful
engraftment and an initial proliferative phase, the growth ofA B
C
FIGURE 2 | General Mef2 signatures but also Treg-specific signatures are altered in Mef2c-/- Tregs. (A) Volcano plot illustrating the statistical significance and the
fold change for genes differentially expressed in Mef2c-/- Foxp3+ Tregs in respect to WT Treg cells. (B) GSEA plots obtained by using the indicated gene-sets and
as dataset the transcriptome of WT or Mef2c-/- Tregs. (C) mRNA expression levels of the indicated genes, expressed as a ratio between Mef2c-/- and WT Tregs
(t-test between the two groups for each gene, *p < 0.05, **p<0.01, ***p<0.005).July 2021 | Volume 12 | Article 703632
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completely cleared in all of the 10 Mef2c-/- mice evaluated
(Figure 5A , with individual growth curves shown in
Supplementary Figure 2). Equal proportions of CD4+Foxp3+
and CD4+Foxp3+Ctla4+ cells were observed in the draining lymph
nodes and spleens of WT and Mef2c-/- mice (Figures 5B, C),
while Mef2c-/- Tregs showed impaired production of IL-10
(Figures 5B, C). The fast kinetics of tumor rejection did not
allow us to quantify the tumor infiltration of CD4+ and CD8+
cells in Mef2c-/- mice, but we observed higher activation (CD44high/
CD62Llow) and greater IFN-g production by CD4 and CD8
(Figures 5D, E) T cells in the tumor-draining lymph nodes and
spleens of Mef2c-/- mice versus WT tumor-bearing mice. As with
the allograft data (Figure 4), these tumor studies indicated impaired
Treg function in vivo after conditional Mef2c deletion. Together,
these data are indicative of a marked impairment of Mef2c-/- TregsFrontiers in Immunology | www.frontiersin.org 6in vivo with characteristics and a magnitude of responses very
similar to those described for the conditional deletion ofMef2d (18).DISCUSSION
While our in vitro analysis suggested Mef2c-/- Tregs have
enhanced suppressive function, our molecular, biochemical and
in vivo data all clearly point to disruption of normal Treg function
upon deletion ofMef2c. Such a disconnect has been reported by us
(15) and others (41–43) and is thought to reflect the limitations of
the standard in vitro Treg suppression assay. Indeed, the originator
of the in vitro Treg suppression assay has reviewed this topic (44),
concluding that there are dozens of examples of genes whose
deletion in Tregs has differing effects in vitro and in vivo, and that
there is major need for improvements to the in vitro assay so as toA B
D E F G
H
C
FIGURE 3 | Mef2c depletion switches on Hdac9 transcription and triggers a feedback response that limits the transcriptional activity of Mef2d. (A) GSEA plots
obtained by using the transcripts significantly induced (left) or repressed (right) in Mef2d-/- Tregs (18) as gene-sets and the transcriptome of WT or Mef2c-/- Tregs as
dataset. (B) Heat-map representing the z-scores of the indicated transcripts in Mef2d-/- and Mef2c-/- Tregs in respect to WT Tregs. (C) mRNA expression levels of
the indicated genes, expressed as a ratio between Mef2c-/- and WT Tregs (t-test between the two groups for each gene, n = 5, **p < 0.01). (D) Immunoblot
analysis of HDAC9 in WT and Mef2c-/- Tregs, as indicated. Actin was used as loading control. (E) Histogram representing the qPCR results obtained in freshly
isolated WT and Mef2c-/- Tregs after the ChIP with H3K27ac or IgG antibodies. Above the histogram we included the representation of the genomic locus of Hdac9.
The red square indicates the position of the amplified region in respect to the leading TSS (n = 3, **p < 0.01). (F) GSEA plot obtained by using the transcripts
significantly repressed in Mef2c-/- Tregs as gene-set and the transcriptome of WT or Hdac9-/- Tregs (33) as dataset. (G) Lysates from freshly isolated WT or
Mef2c-/- Tregs were pulled down with anti-Mef2or IgG Ab (1mg). 1/50 total lysates have been included and marked as input. (H) Histogram representing the qPCR
results obtained in freshly isolated WT and Mef2c-/- Tregs after the ChIP with the indicated antibodies. For each gene analyzed, we included the illustration of the
genomic locus in which the red squares point to the position of the amplified region in respect to the leading TSS (n = 3, *p < 0.05).July 2021 | Volume 12 | Article 703632
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another example of this disconnect and going forward have
chosen to focus on the molecular, biochemical and in vivo
effects of Mef2c deletion on Treg biology.Frontiers in Immunology | www.frontiersin.org 7The complex and dynamic nature of the protein complexes
that dictate Treg identity obey biological, biochemical and
epigenetic features that similarly control many other
differentiative and adaptive processes (11). Similarly to Foxp3,A B
D
C
FIGURE 4 | Mef2c deletion dampens Treg function in vivo. (A) Schematic illustrating cardiac allografting procedure. (B) Differently from WT recipients, Mef2c-/- mice
acutely rejected cardiac allografts (BALB/c->C57BL/6) despite costimulation blockade with CD154 mAb/DST; n = 5/group (Tukey’s multiple comparison test, p <
0.01). The cardiac allografting was repeated twice with similar results. (C) Histology of transplanted hearts show focal interstitial infiltrates in WT recipients (Cre) and
dense mononuclear infiltrates with multifocal myocyte necrosis and vascular injury in conditionally deleted Mef2c-/- recipients (bar = 100 µM). (D) qPCR results of the
expression of the indicated genes in samples collected 21 days after cardiac allografting in WT (Cre) and Mef2c–/– mice (n = 6/group). ns, not significant.July 2021 | Volume 12 | Article 703632
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activators and co-repressors to pursue the plastic control of the
transcriptional program (19). In Treg cells, Mef2d is required to
sustain and integrate the Foxp3 transcriptional repertoire (18);
Mef2d deletion in Foxp3+ cells impairs the acquisition of an
eTreg phenotype and leads to an increase in anti-cancer
immunity and transplant rejection (18). Although Mef2c is
expressed at very low levels in Tregs, Mef2c-/- mice rapidly
reject heart allografts and restrain cancer growth in syngeneic
models, similarly to Mef2d-/- mice. The de-repression of Hdac9Frontiers in Immunology | www.frontiersin.org 8achieved after Mef2c KO plays a central key role in blocking
Mef2d responses and Treg immune suppressive functions.
Hdac9 is transcribed by Mef2d as part of a physiological
feedback aimed at switching-off Mef2d transcriptional program
(23, 45). This feedback mechanism is active in Tregs (18) and
Hdac9-/- Tregs have increased suppressive functions (33, 46).
Interestingly, the strength of this feedback mechanism is altered
in some pathological conditions, such as cardiac hypertrophy
(47) and cancer (23, 48). However, the genetic and epigenetic




FIGURE 5 | Mef2c deletion in Foxp3+ Tregs promotes anti-cancer immunity. (A) Graphs representing the tumor growth in 10 WT and 10 Mef2c-/- mice during a
19-day-long observation period after the subcutaneous injection of 1.2x106 TC1 cells. The experiment was repeated twice with similar results (t-test between the two
groups for each time point, *p < 0.05, ***p < 0.005). (B, C) Analysis of CD4+Foxp3+, CD4+Foxp3+Ctla4+ and CD4+Foxp3+IL-10+ populations in single-cell
suspensions obtained from the draining lymph node and spleen harvested from four representative mice injected as in Figure 5. In the case of IL-10 production,
isolated cells were stimulated for 4 h with PMA/ionomycin before the staining. (n = 4, t-test between the two groups, **p < 0.01, ***p < 0.005). (D, E) Analysis of the
activation status and IFN-g production in conventional CD4+ T cells and CD8+ T cells in single-cell suspensions obtained from the draining lymph node and spleen
harvested from four representative mice injected as in (A). (n = 4, t-test between the two groups, **p < 0.01, ***p < 0.005).July 2021 | Volume 12 | Article 703632
Di Giorgio et al. Mef2c and Foxp3+ Treg CellsHere we have added a new level of complexity to the well-
known molecular circuit involving Mef2 TFs and their strongest
repressors, the class IIa HDACs. We report the existence of an
alternative mechanism through which two different paralogues
of Mef2 family, Mef2c and Mef2d, respectively repress and
promote Hdac9 transcription. Although we have not yet
clarified the detailed mechanism by which Mef2c maintains the
repression of Hdac9, a suggestive hypothesis that is corroborated
by the first ChIP data is that two antagonist complexes are
assembled on Hdac9 promoter: an activator complex bound to
Mef2d and a repressive one complexed to Mef2c. The presence of
such delicate balances underlines the central role played by Mef2
TFs in supporting Treg identity and encourages further studies to
clarify the molecular details of these interactions.
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Supplementary Figure 1 | Treg suppression assays showing proliferation of
CD4 T cell responders (upper panel) and CD8 T cell responders (low panel). These
are from the same experiment performed in triplicate (Trial 2) as shown in Figure 1F
(total T cell responders). These experiments were repeated two times by using three
mice per group.
Supplementary Figure 2 | Mef2c deletion promotes anti-cancer immunity.
Graphs representing the detailed tumor growth data for each of the 10 WT and 10
Mef2c-/- mice during a 19-day-long observation period after the subcutaneous
injection of 1.2x106 TC1 cells. The experiment was repeated twice with
comparable results.REFERENCES
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